BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt…
Author: Business Wire
Resumen: Satralizumab de Chugai obtiene la designación de terapia innovadora de la FDA para la neuromielitis óptica y enfermedades del espectro de la neuromielitis óptica
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado que la Administración de Alimentos y Fármacos de EE. UU. (FDA en sus siglas en inglés) ha concedido la designación de terapia revolucionaria al antic…
Samenvatting: Chugai’s Satralizumab ontvangt FDA doorbraaktherapie-aanduiding voor Neuromyelitis Optica en Neuromyelitis Optica Spectrumstoornissen
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kondigde aan dat de Amerikaanse Food and Drug Administration (FDA) doorbraaktherapie-aanduiding voor Chugai’s anti-interleukine-6 (IL-6) receptor gehumaniseerde recycling antil…
FDA簽發中外製藥的satralizumab為視神經脊髓炎及泛視神經脊髓炎的突破性治療藥物認證
東京–(BUSINESS WIRE)–(美國商業資訊) — 中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO: 4519)宣布，美國食Ø…
La FDA accorde au satralizumab de Chugai la désignation de thérapie novatrice pour le traitement de la neuromyélite optique et des maladies du spectre de la neuromyélite optique
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que l’Agence américaine des produits alimentaires et médicamenteux (Food and Drug Administration, FDA) a octroyé la désignation de thérapie novatrice à l’anticorps de recyclage humanisé anti-récepteur de l’interleukine-6 (IL-6) de Chugai, le satralizumab, un médicament expérimental pour le traitement de la neuromyélite optique et des maladies du spectre de la neuromyélite optique (NMO/NMOSD). « Le satralizumab est
Ophthalmic Ultrasound Systems Markets with Forecasts from 2018 to 2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Ultrasound Systems Market – Forecasts From 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic ultrasound systems market is expected to reach US$3.167 billion by 2023 from US$2.008 billion in 2017 growing at a CAGR of 7.89%. The market is expected to show a significant growth during the given forecast period. The growth may be attributed to the increasing prevalence of the eye diseases needing ophthalmic ultras
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies desig…
Global Ocular Inflammation Treatment Market (2019-2023) is Expected to Grow at a CAGR of More Than 6% – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ocular Inflammation Treatment Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The ocular inflammation treatment market will register a CAGR of more than 6% by 2023. The technological advances in drug delivery to push growth in the market. The increasing need for novel drug delivery systems has led to the advent of intravitreal implants, which are small hair-stranded sized devices that are implanted into the middle layer of the e
Satralizumab von Chugai erhält von FDA den Status „Breakthrough Therapy“ für Neuromyelitis optica und Neuromyelitis-optica-Spektrum-Erkrankungen
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab bekannt, dass die US-amerikanische Zulassungsbehörde FDA den Status „Breakthrough Therapy“ (Durchbruchtherapie) für Chugais humanisierten, rezyklierenden An…
Physicians’ Education Resource® Presents the 16th Annual Winter Lung Cancer Conference™
CRANBURY, N.J.–(BUSINESS WIRE)–Physicians’ Education Resource® Presents the 16th Annual Winter Lung Cancer Conference™
Riassunto: Satralizumab di Chugai ha ottenuto dalla FDA la designazione di terapia innovativa per la neuromielite ottica e i disturbi dello spettro della neuromielite ottica
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) ha annunciato in data odierna che l’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Administration, FDA) ha concesso la designazione di terap…
Ophthalmics – Global Partnering Report (2012-2018): Updated Deal Trends, Players and Financials – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmics Partnering 2012-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering. Global Ophthalmics Partnering 2012 to 2018 provides the full collection of Ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2012. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology.
Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
TOKYO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/BTD?src=hash" target="_blank"gt;#BTDlt;/agt;–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakt…
Intraocular Lens Market – Global Forecasts from 2018 to 2023 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Intraocular Lens Market – Forecasts From 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The Intraocular lens market is projected to grow at a CAGR of 5.98% to reach US$14.759 billion by 2023, from US$10.416 billion in 2017. Growing prevalence of eye diseases like cataracts and increase in initiatives taken by the government to eliminate avoidable blindness are expected to fuel the growth of the intraocular lens market. According to World
CURE Media Group Honored in 20th Anniversary Digital Health Awards Fall 2018 Session
CRANBURY, N.J.–(BUSINESS WIRE)–CURE Media Group Honored in 20th Anniversary Digital Health Awards Fall 2018 Session
Eye Center of Northern Colorado Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts
FORT COLLINS, Colo.–(BUSINESS WIRE)–Eye Center of Northern Colorado joins the AcuFocus IC-8® Lens clinical study for patients with cataracts.
Ophthalmology Disease & Epidemiology Overview 2018 Featuring Alimera Sciences, Allergan, Regeneron, Bayer, Santen, Roche, Genentech, & Novartis – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology – Disease & Epidemiology Overview” report from Decision Resources Group has been added to ResearchAndMarkets.com’s offering. This report provides a disease market overview for each indication and global epidemiology overviews for each indication. The Ophthalmology Disease & Epidemiology Overview report provides disease market overviews and global epidemiology overviews for 4 indications in the Ophthalmology therapy area: Diabetic Macular Edema
Retinopathy of Prematurity – 2018 Pipeline Insight Featuring Biomar Microbial Technologies, F. Hoffmann-La Roche, Recordati, Radikal Therapeutics, EyeGene, and Insmed – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinopathy of Prematurity – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Retinopathy of Prematurity development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by development
Anterior Uveitis – Pipeline Insight, 2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Anterior Uveitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated
Rhino-Conjunctivitis – Pipeline Insight, 2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Rhino-Conjunctivitis – Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Rhino-Conjunctivitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, as